Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00058924" target="_blank" >RIV/00023001:_____/14:00058924 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985823:_____/14:00427797

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/1755-5922.12061/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/1755-5922.12061/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/1755-5922.12061" target="_blank" >10.1111/1755-5922.12061</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels

Popis výsledku v původním jazyce

AimsStatins have antiinflammatory effects and are known to decrease risk of cardiovascular events and to reduce serum levels of C-reactive protein (CRP), a widely studied biomarker and potential mediator of inflammation and heart disease. However, it isunclear whether statins can block pro-inflammatory effects of human CRP independent of their ability to reduce serum levels of human CRP. Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. Methods and ResultsWe studied the antiinflammatory effects of rosuvastatin in spontaneously hypertensive rats (SHR) transgenically expressing human CRP (CRP-transgenic SHR) and in nontransgenic SHR lacking human CRP (nontransgenic SHR). The CRP-transgenic SHR is characterized by increased serum levels of human CRP and inflammation. In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL

Název v anglickém jazyce

Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels

Popis výsledku anglicky

AimsStatins have antiinflammatory effects and are known to decrease risk of cardiovascular events and to reduce serum levels of C-reactive protein (CRP), a widely studied biomarker and potential mediator of inflammation and heart disease. However, it isunclear whether statins can block pro-inflammatory effects of human CRP independent of their ability to reduce serum levels of human CRP. Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. Methods and ResultsWe studied the antiinflammatory effects of rosuvastatin in spontaneously hypertensive rats (SHR) transgenically expressing human CRP (CRP-transgenic SHR) and in nontransgenic SHR lacking human CRP (nontransgenic SHR). The CRP-transgenic SHR is characterized by increased serum levels of human CRP and inflammation. In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cardiovascular therapeutics

ISSN

1755-5914

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

59-65

Kód UT WoS článku

000332766000006

EID výsledku v databázi Scopus

—